(Q54977319)

English

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

phase II clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

4

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

object named as

Norbert Ifrah

20

0 references

Giovanni Martinelli

5

object named as

Giovanni Martinelli

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

Jorge Eduardo Cortes

1

object named as

Jorge Cortes

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

Hartmut Döhner

3

object named as

Hartmut Döhner

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

9

object named as

Hervé Dombret

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

10

object named as

Elihu Estey

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

Stephen A. Strickland

11

object named as

Stephen Strickland

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

24

object named as

Mark Levis

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

Jessica K Altman

12

object named as

Jessica K Altman

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

Philippe Rousselot

7

object named as

Philippe Rousselot

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

19

object named as

Eunice S Wang

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

Tibor Kovacsovics

6

object named as

Tibor Kovacsovics

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

Alexander E Perl

2

object named as

Alexander E Perl

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

21

object named as

Guy Gammon

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

22

object named as

Denise Trone

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

16

object named as

Nigel Russell

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

author name string

Björn Steffen

8

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

Claudia D Baldus

13

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

Alan Burnett

14

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

Alwin Krämer

15

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

Neil P Shah

17

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

Catherine C Smith

18

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

Deborah Lazzaretto

23

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

publication date

30 May 2018

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

FLT3: ITDoes matter in leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute myeloid leukemia and myelodysplastic syndromes in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gender-specific differences in the QT interval and the effect of autonomic tone and menstrual cycle in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Greater quinidine-induced QTc interval prolongation in women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of FLT3 Internal Tandem Duplication and D835 Mutations by a Multiplex Polymerase Chain Reaction and Capillary Electrophoresis Assay

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of patients with acute myelogenous leukemia after second salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of c-Kit by tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The myth of the second remission of acute leukemia in the adult

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

FLT3 inhibitors in AML: are we there yet?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930240-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(18)30240-7

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

release_xgfemfqrzfcqtdrn5bd3skiiym

1 reference

https://api.fatcat.wiki/v0/release/xgfemfqrzfcqtdrn5bd3skiiym

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

https://api.fatcat.wiki/v0/release/xgfemfqrzfcqtdrn5bd3skiiym

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 June 2018

http://europepmc.org/abstract/MED/29859851

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54977319&oldid=1858167118"